Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 801 participants.

Also called NCT01294462

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 801 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01294462
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan, South Korea, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01294462. Randomized; quadruple masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2012-07 (actual). Results posted on 2014-05-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)
Condition
Acute Coronary Syndrome
Intervention (Drug)
Ticagrelor
Intervention (Drug)
Clopidogrel
Intervention (Drug)
Acetylsalicylic acid ASA
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct01294462
Content hash
93ffdf6b97c44d674735cabf3a1f59f033ecf927b4e41fbaca6c90c582f3fae6